pSivida Corp. Reports Fourth Quarter and Fiscal Year 2011 Results

WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing
sustained release, drug delivery products for treatment of
back-of-the-eye diseases, including clinical stage product candidates
for the treatment of diabetic macular edema (DME), uveitis affecting the
posterior segment of the eye (posterior uveitis) and glaucoma, today
announced financial results for its fourth quarter and fiscal year ended
June 30, 201.

“We believe we have made very good progress this year in developing our
clinical stage product pipeline with both our partnered and unpartnered

At June 30 2011, cash, cash equivalents and marketable securities
totaled $24.1 million compared to $17.6 million at June 30, 2010.

“We believe we have made very good progress this year in developing our
clinical stage product pipeline with both our partnered and unpartnered
programs,” said Paul Ashton, President and CEO. “ILUVIEN® for DME,
partnered with Alimera Sciences, is well along, with action by the FDA
expected in November. We are very optimistic about this product,
particularly in light of the 3-year data and subgroup analysis provided
to the FDA in May.”

“In addition to ILUVIEN, we have two other product candidates in
clinical trials. We announced earlier today the opening of an
Investigational New Drug Application (IND) for an investigator-sponsored
trial in posterior uveitis. This trial will use inserts of the same
design as those used in the ILUVIEN for DME trials. Our collaboration
agreement with Alimera allows us to reference the DME regulatory
filings, including the NDA (including clinical, safety and stability
data from the Phase III trials), which provides the potential for an
abbreviated clinical development and regulatory approval process. We
also announced in June that the bioerodilble latanoprost insert for
glaucoma (partnered with Pfizer) is in a clinical trial,” said Dr.

On May 12, 2011, Alimera resubmitted the NDA for ILUVIEN for DME, an
injectable Durasert™ insert delivering the corticosteroid fluocinolone
acetonide (FAc), to respond to the FDA’s Complete Response Letter.
Alimera has reported that it expects a response from the FDA in November

Under the June 2011 amended and restated collaboration agreement with
Pfizer, the Company granted Pfizer an exclusive option under various
circumstances to license the development and commercialization worldwide
of an injectable, bioerodible sustained release insert delivering
latanoprost for human ophthalmic disease or conditions other than
uveitis. Pfizer made an upfront payment of $2.3 million, and the Company
has the right to develop this product candidate through Phase II
clinical trials. In June 2011, the Company announced a Phase I/II dose
escalating study designed to assess the safety and efficacy of this
insert in patients with elevated intraocular pressure.

On September 12, 2011, the Company announced the opening of an IND for
an investigator-sponsored Phase I/II clinical trial to assess the safety
and efficacy of the Company’s injectable, sustained release insert
delivering FAc for the treatment of uveitis affecting the posterior
segment of the eye. The inserts in the trial deliver the high and low
dose of FAc studied in the Phase III trials of ILUVIEN for DME. The
Company licensed Alimera the right to use this insert for the treatment
and prevention of eye diseases in humans other than uveitis.

Revenues for the year ended June 30, 2011 totaled $5.0 million compared
to $23.1 million for the year ended June 30, 2010. Fiscal 2011 revenues
were primarily attributable to the June 2011 amendment and restatement
of the Company’s collaboration agreement with Pfizer, while the prior
year’s revenues were predominantly due to payment in full by Alimera of
a $15.0 million conditional note and recognition of deferred revenue
from the Alimera agreement, which was completed in the fiscal 2010
second quarter. For the year ended June 30, 2011, the Company reported a
net loss of $8.6 million, or $0.44 per share, compared to net income of
$8.8 million, or $0.46 per diluted share, for the prior fiscal year.

Revenues for the fiscal 2011 fourth quarter were $3.7 million compared
to $15.7 million a year earlier, reflecting revenues from the Pfizer
agreement in fiscal 2011 and the Alimera note repayment in the fiscal
2010 quarter. The Company reported a net loss of $140,000, or $0.01 per
share, for the fourth quarter ended June 30, 2011, compared to net
income of $13.1 million, or $0.68 per diluted share, for the fourth
quarter of the prior year.

Today’s Conference Call Reminder

pSivida Corp. will host a live webcast and conference call today,
September 12, 2011, at 4:30 pm ET. The conference call may be accessed
by dialing (866) 203-2528 from the U.S. and Canada, or (617) 213-8847
from international locations, passcode 80736748. The conference can also
be accessed on the pSivida Corp. website at
A replay of the call will be available approximately two hours following
the end of the call through September 19, 2011. The replay may be
accessed by dialing (888) 286-8010 within the U.S. and Canada or (617)
801-6888 from international locations, passcode 46828003.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™.
ILUVIEN® for the treatment of Diabetic Macular Edema, which is licensed
to Alimera Sciences, Inc., is pSivida’s most advanced product candidate
and is currently under review by the U.S. Food and Drug Administration.
An investigator-sponsored Investigational New Drug application opened
for an injectable insert to treat posterior uveitis of the same design
as ILUVIEN for DME, and an investigator-sponsored trial is ongoing for
an injectable, bioerodible insert to treat glaucoma and ocular
hypertension. pSivida’s two FDA-approved products, Retisert® and
Vitrasert®, are implants that provide long-term, sustained drug delivery
to treat two other chronic diseases of the retina.

ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements: ability to
obtain additional capital if needed; future losses; impairment of
intangibles; fluctuations in the fair values of certain outstanding
warrants; fluctuations in operating results; decline of royalty income
from Bausch & Lomb; Alimera’s ability to obtain regulatory approval of
ILUVIEN; Alimera’s ability to successfully commercialize ILUVIEN if
approved; risk/benefit profile of ILUVIEN; timeliness of approval, if
any, of ILUVIEN and any limitations on uses thereof; ability to complete
clinical trials, reference data and obtain regulatory approval of other
product candidates; ability to find partners to develop and market
products; termination of license agreements; competition; market
acceptance of products and product candidates; reduction in use of
products as a result of future publications; ability to protect
intellectual property or infringement of others’ intellectual property;
retention of key personnel; product liability; consolidation in the
pharmaceutical and biotechnology industries; compliance with
environmental laws; manufacturing risks; risks and costs of
international business operations; credit and financial market
conditions; legislative or regulatory changes; volatility of stock
price; possible dilution through exercise of outstanding warrants and
stock options or future stock issuances; possible influence by Pfizer;
ability to pay any registration penalties; absence of dividends; and
other factors described in our filings with the Securities and Exchange
Commission. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. Our
forward-looking statements speak only as of the dates on which they are
made. We do not undertake any obligation to publicly update or revise
our forward-looking statements even if experience or future changes
makes it clear that any projected results expressed or implied in such
statements will not be realized.


(In thousands except per share amounts)


Three Months Ended Year Ended
June 30, June 30,


2010 2011


Collaborative research and development $ 3,394 $ 15,328 $ 3,612 $ 22,570
Royalty income 321 394 1,353 483
Total revenues   3,715



4,965     23,053  
Operating expenses:
Research and development 1,851 1,785 6,864 6,994
General and administrative 2,172 1,763



Total operating expenses   4,023  


3,548     14,968    



Operating (loss) income


(308 )   12,174     (10,003 )  



Other income (expense):

Change in fair value of derivatives

10 870 1,140 (339 )
Interest income 11 25 30 27
Other expense, net (2 ) (11 ) (13 ) (3 )



Total other income (expense)   19     884




(315 )
(Loss) income before income taxes (289 ) 13,058 (8,846


Income tax benefit (expense) 149 15 218 (23 )


Net (loss) income $


) $ 13,073   $ (8,628 ) $ 8,753  


Net (loss) income per share:

Basic $ (0.01 ) $ 0.71   $ (0.44 ) $ 0.48  


Diluted $ (0.01 ) $ 0.68   $ (0.44 ) $ 0.46  
Weighted average common shares outstanding:

20,745     18,531     19,489    





20,745     19,217  







(In thousands)


June 30, June 30,




Current assets:
Cash, cash equivalents and marketable securities $ 24,128 $ 17,565
Other current assets






Total current assets

25,366 19,034
Intangible assets, net 21,564 23,877

Other assets

183 103


Total assets $ 47,113   $ 43,014  
Liabilities and stockholders’ equity

Current liabilities:
Accounts payable and accrued expenses $ 1,650 $ 1,545
Deferred revenue 3,212 79
Derivative liabilities 170 1,310
Total current liabilities 5,032 2,934
Deferred revenue 4,635 6,817
Deferred tax liabilities 13 222

Total liabilities



Stockholders’ equity:
Capital 262,927 250,815
Accumulated deficit (226,923 ) (218,295 )
Accumulated other comprehensive income 1,429 521
Total stockholders’ equity  

37,433     33,041  
Total liabilities and stockholders’ equity

$ 47,113


$ 43,014  


US Public Relations
Beverly Jedynak
E. Janis & Company, Inc
Tel: +1 (312) 943 1123

Brian Leedman
Vice President, Investor Relations
Tel: +61 8 9443 4949

RSS From Medical Design & Outsourcing

  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]
  • Tackling chronic sinusitis by addressing underlying factors
    The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They […]
  • Implantable “artificial pancreas” could help diabetes patients control their blood sugar
    Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the American Chemical Society (ACS) journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as […]
  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]


  1. says

    I simply want to mention I am all new to blogging and site-building and seriously savored this web-site. Most likely I’m likely to bookmark your website . You definitely have fabulous well written articles. Thanks a bunch for sharing your blog.

Leave a Reply